AUTHORS
David Tofovic, MD, Alexander K Glaros, MD2, Jean-Benoit Arlet, Pr3, Bernhards Ogutu, MD4, Scott Alan Peslak I, MD,PhD5, Santosh L Saraf, MD6, Ana Silva-Pinto, MD, PhD7, Kaoutar Hafraoui8, Mike Callaghan, MD9, Pranita Chilakamarri, PharmD10, Abdulafeez Deji Oluyadi, PharmD11, Tao Song12, Amber Yates, MD13, Ahmar U. Zaidi, MD14, Andrew Campbell, MD15
AFFILIATIONS
1 Division of Cardiology, University of Illinois Chicago, Chicago, Illinois, United States
2 Central Michigan University, Children’s Hospital of Michigan, Detroit, Michigan, United States
3 Service de Médecine Interne, French Referral Sickle Cell Disease Center, Hôpital Européen Georges Pompidou, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France
4 Center for Research in Therapeutic Sciences (CREATES), Strathmore University, Nairobi, Kenya, Centre for Clinical Research, Kenya Medical Research Institute, Kisumu, Kenya
5 University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
6 University of Illinois Chicago, Chicago, Illinois, United States
7 Ribeirão Preto School of Medicine, Universidade de São Paulo, São Paulo, Brazil
8 CHU Liège, Liège, Belgium
9 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
10 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
11 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
12 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
13 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
14 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
15 Children’s National Hospital, Washington, District of Columbia, United States
ABSTRACT
Introduction: Cardiovascular complications are a leading cause of morbidity and mortality in adults with sickle cell disease (SCD). Chronic anemia and ongoing hemolysis drive a persistent high-output circulatory state, endothelial dysfunction, oxidative stress, and vasculopathy, which together can contribute to maladaptive cardiac changes in SCD. This remodeling is characterized by increased left ventricular hypertrophy, impaired diastolic relaxation, multi-chamber enlargement, and elevated filling pressures. Novel therapies targeting these maladaptive changes are needed. Mitapivat is an oral activator of pyruvate kinase (PK; including the red blood cell–specific PKR and the PKM2 isoforms). In addition to its erythropoietic effects, mitapivat has been shown to activate PKM2 in cardiac tissue. In a murine model of β-thalassemia, another hemolytic anemia, mitapivat improved inflammatory, pro-fibrotic cardiomyopathy associated with cardiac PKM2 dysregulation. Separately, in a pressure-overload model of cardiac fibrosis, mitapivat-mediated PKM2 activation reduced fibrosis and improved diastolic function. The double-blind placebo-controlled phase 3 RISE UP trial of mitapivat in SCD (NCT05031780) met the primary endpoint of hemoglobin (Hb) response and demonstrated improvements in hemolysis. Additional clinical benefits were seen in the Hb responder group. This analysis describes the cardiac effects of mitapivat in RISE UP.
Methods: The study design of RISE UP was previously described (Andemariam et al. 2026 European Hematology Association Congress, Stockholm, Sweden). Patients were randomized 2:1 to receive mitapivat 100 mg orally or placebo, twice-daily for 52 weeks. Patients underwent transthoracic echocardiography (TTE) at baseline and Week 52. All TTEs were interpreted at individual study sites, with measurements obtained and calculated according to the American Society of Echocardiography standards. Hb response was defined as a ≥1.0 g/dL increase from baseline in average Hb concentration from Week 24 to Week 52. Patients who met this criterion were classified as Hb responders and those who did not as Hb nonresponders. Cardiac parameters at baseline and Week 52 are presented descriptively for the mitapivat-treated Hb responders, Hb non-responders, and patients who received placebo.
Results: A total of 207 patients were randomized to mitapivat (n=138) or placebo (n=69); 56 mitapivat-treated patients (40.6%) were classified as Hb responders. Hb responders showed a reduced left ventricular mass index (LVMI) from baseline to Week 52 compared with Hb non-responders and placebo-treated patients (mean change [SD]: −5.9 [30.8] vs +5.8 [27.2] and +4.6 [34.5] g/m2, respectively; n=40, 45, and 27 patients with baseline and Week 52 assessments). Similarly, Hb responders displayed greater reductions in left atrial volume index (LAVI) from baseline to Week 52 compared with Hb non-responders and placebo (mean change [SD]: −4.7 [16.2] vs −1.7 [11.6] and −0.2 [11.6] mL/m2, respectively; n=35, 41, and 27 patients). No relevant differences were seen across groups from baseline to Week 52 for Hb responders, Hb non-responders, and placebo recipients in left ventricular ejection fraction, left ventricular end diastolic diameter, mitral E/A ratio, lateral E/e’ ratio, and peak tricuspid regurgitant velocity. This may be due to a low burden of diastolic impairment and elevated right-sided filling pressures in the study population or the brief duration of follow-up.
Conclusions: Prior evidence has demonstrated maladaptive cardiac remodeling in SCD and its association with morbidity and mortality. In this study, mitapivat-treated Hb responders had reductions in LVMI and LAVI at 1 year, suggesting favorable cardiac remodeling within this subgroup. These findings are alongside previously described clinical benefits in Hb responders, indicating that the antihemolytic effect of mitapivat may be a key driver of these cardiac improvements. Further, pre-clinical evidence in hemolytic anemia and pressure-overload models has shown that mitapivat, through PKM2 activation, attenuates cardiac fibrosis, suggesting a potential dual cardiac benefit with this therapy.
DISCLOSURES
David Tofovic, MD: Agios Pharmaceuticals, Inc. - Consultancy (Includes expert testimony)